During the BIO 2026 event, biotech executives gathered to discuss pressing issues affecting the industry, particularly the challenges posed by Chinese biotech.
Concerns were also raised regarding the profitability of artificial intelligence within the sector, highlighting the need for advancements in this area.
Additionally, the durability of former President Trump's drug price policies was a significant topic of conversation, reflecting ongoing uncertainties in the regulatory landscape.